Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

SA Transcripts 161.45K Followers Follow Stoke Therapeutics, Inc. ( STOK ) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDT Company Participants Thomas Leggett - Chief Financial Officer Ian Smith - CEO & Director Barry Ticho - Chief Medical Officer Jason Hoitt - Chief Patient Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Yaron Werber - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Kevin Strang - Goldman Sachs Group, Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Adam Ferrari - JPMorgan Chase & Co, Research Division Delma Caiati Guofang Li - Wolfe Research, LLC Presentation Operator Hello, and welcome to the Stoke Therapeutics Second Quarter 2026 Business and Financial Update. [Operator Instructions] Be advised that today's conference is being recorded. It is now my pleasure to introduce CFO, Thomas Leggett. Thomas Leggett Chief Financial Officer Good evening, and welcome to Stoke Therapeutics Second Quarter 2026 Business Update Conference Call. I'm Thomas Leggett, the Chief Financial Officer of Stoke Therapeutics. Joining me on today's call are Ian Smith, our Chief Executive Officer, Dr. Barry Ticho, Chief Medical Officer; and Jason Hoitt, Chief Patient Officer. As a reminder, today's webcast presentation is available in the Investors section of our website. This webcast is being recorded and will be available for replay later this evening. Before we begin, please note that today's discussion includes forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Please refer to our filings with the SEC for additional information. On today's call, we will review recent progress across the breadth of our business. Ian will start with an overview and share an update on the ongoing Phase III EMPEROR study. This study is